Rezolute Reports Q3 Net Loss of $16.17 Million, EPS -$0.16
RZLT has more than doubled off its 52-week low of $1.07.
Summary
Rezolute reported a Q3 net loss of $16.17 million, translating to an EPS of -$0.16, with operating expenses reaching $17.37 million. These financial results indicate continued significant cash burn and losses for the company. While the company recently announced positive expanded results from its Phase 3 sunRIZE study, these Q3 figures highlight the ongoing financial challenges. This update follows the previous 10-Q which also indicated a wider net loss. Traders will be closely watching for further updates on the commercialization strategy for its drug candidates and any future financing activities to support its operations.
At the time of this announcement, RZLT was trading at $3.30 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $315.8M. The 52-week trading range was $1.07 to $11.46. This news item was assessed with negative market sentiment and an importance score of 8 out of 10. Source: Reuters.